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ABSTRACT 
Pathologies affecting the posterior segment are one of the major causes of 
blindness in developed countries and are becoming more prevalent due to the increase 
in society longevity. Sucessful therapy of diseases affecting the back of the eye requires 
effective concentrations of the active substance mantained during a long period of time 
  
in the intraocular target site. Treatment of vitreoretinal diseases often include repeated 
intravitreous injections that are associated with adverse effects. Local administration of 
biodegradable microspheres offers an excellent alternative to multiple administrations, 
as they are able to deliver the therapeutic molecule in a controlled fashion. Furthermore, 
injection of microparticles is performed without the need for surgical procedures. As most 
of the retinal diseases are multifactorial, microspheres result especially promising 
because they can be loaded with more than one active substance and complemented 
with the inclusion of additives with pharmacological properties. Personalized therapy can 
be easily achieved by changing the amount of administered microspheres. Contrary to 
non-biodegradable devices, biodegradable PLA and PLGA microspheres disappear from 
the site of administration after delivering the drug. Furthermore, microspheres prepared 
from these mentioned biomaterials are well tolerated after periocular and intravitreal 
injections in animals and humans. After injection, PLA and PLGA microspheres suffer 
aggregation behaving like an implant. Biodegradable microspheres are potential tools in 
regenerative medicine for retinal repair. According to the reported results, presumably a 
variety of microparticulate formulations for different ophthalmic therapeutic uses will be 
available in the clinical practice in the near future. 
 
1. Introduction 
 
Pathologies affecting the posterior segment of the eye are one of the major causes 
of blindness in developed countries. These diseases include uveitis, diabetic retinopathy, 
macular edema, endophthalmitis, proliferative retinopathy, age related macular 
degeneration and glaucoma, among others. Generally, back of the eye diseases are 
chronic and degenerative.and some of them are related to elderly. Sucessful treatments 
of vitreoretinal diseases require effective concentrations of the active substance 
mantained during long periods in the target site. Statics barriers (different corneal layers, 
sclera, retina, blood aqueous and blood retinal barriers), dynamic barriers (tear dilution, 
conjunctival and choroidal blood flow, and lymphatic clearance) as well as efflux pumps, 
effectively limit the drug access to the posterior segment (Gaudana et al., 2010). Four 
routes of administration can be theoretically employed to deliver active substances to 
  
treat retinal diseases: topical, systemic, intraocular and periocular (Herrero-Vanrell et al., 
2001). The poor bioavailability of topically administered drugs limits their access to 
intraocular tissues. Systemic administration requires high doses to achieve adequate 
therapeutic levels of the drug in the eye with the risk of systemic adverse effects. 
Intraocular local drug administration includes injections into the anterior chamber of the 
eye (intracameral), in the vitreous (intravitreal) or into the periocular tissues 
(subconjunctival, sub-Tenon and retrobulbar). Due to the difficulty in the maintenance of 
therapeutic concentrations in the target site, repeated intraocular injections are required 
for a successful therapy causing much inconvenience to patients. Although the periocular 
route is getting more attention, intravitreal injections are still the most employed even 
being associated to non-desired effect. For example, if high doses of the therapeutic 
agent are administered the concentration in the retina can be toxic. Besides, successive 
intravitreal injections are related to adverse effects such as cataracts, retinal detachment, 
and haemorraghes, among others. Moreover, the risk of the non-desired effects 
increases with the number of injections (Herrero-Vanrell et al., 2000). 
Innovative treatments as intraocular drug delivery systems have been developed to 
provide sustained drug concentrations of the active substance in the target site. They 
are constituted by a combination of drugs and biomaterials. Depending on the properties 
of the biomaterial (erodible or biodegradable and non-erodible or non-biodegradable), 
the devices can disappear from the site of administration or remain there during the 
lifetime of patients.  
Depending on their size, devices are classified as implants (>1 mm), microparticles 
(1-1000 μm) and nanoparticles (1-1000 nm). Considering their physical structure they 
are divided into reservoir and matrix systems (Herrero-Vanrell and Cardillo 2010b). 
Implants and microparticles are able to release the active substance during longer 
periods of time compared to nanoparticles (figure 1). Depending on their size, 
implantation procedure requires a surgical incision or a small perforation. Several non-
biodegradable implants and one erodible device have been approved for clinical use. 
Non-biodegradable implants remain inside the eye or need a second surgery procedure 
to be removed. The non-biodegradable devices approved for clinical use are reservoir 
systems constituted by a nucleous of the drug surrounded by a layer of a mixture of 
polymers. They are loaded with antivirals (ganciclovir Vitrasert®) or anti-inflammatory 
drugs (fluocinolone acetonide Retisert™ and Medidur™). There is one biodegradable 
implant (0.45 x 6 mm) made of PLGA (Ozurdex). The matrix device is loaded with 
dexamethasone (700 μg) and is approved for the treatment of retinal vein occlusion, 
diabetic macular edema, uveitis and post-cataract surgery (Herrero-Vanrell et al., 
2011b). 
  
According to their structure, microparticles receive the name of microcapsules for 
reservoir structures or microspheres for matrix systems (Yasukawa et al., 2004). 
Microcapsules are formed by a core containing the drug, which is surrounded by a layer 
of a polymer or a mixture of several polymers. In the microspheres, the active substance 
is dispersed in the polymeric network (figure 2).  
Once administered, microparticles can disappear or remain in the site of 
administration after releasing the drug. In case of chronic posterior segment diseases 
biodegradable microspheres are preferred. Their use as injectable devices has become 
more popular over the last few decades. The main objectives of the development of 
biodegradable microspheres for intraocular drug delivery have been to obtain long-acting 
injectable drug depot formulations and specific drug targeting options. 
Intraocular microparticles allow the release of the encapsulated drug, bypassing the 
blood–ocular barrier. The main advantage of these formulations is that they can release 
the drug over time with one single administration, having the same effect as multiple 
injections. Sustained release of active substances from microspheres reduces the need 
for frequent administrations and enhances patient compliance. This strategy has gained 
a lot of attention, especially in chronic diseases that require low concentrations of an 
active substance for a long period of time (Checa-Casalengua et al., 2011). 
 
Microparticles are good candidates to be used in personalized medicine as different 
amounts of particles can be administered depending on patient needs. For intraocular 
purposes, they must be biocompatible, safe and stable, demonstrating predictable 
degradation kinetics. All these requierements can be achieved by the adjustement of the 
parameters involved in the manufacturing procedure. Furthermore, other factors such as 
chemical modifications of the particle surface can optimize the functionality of the system 
or help induce the desired response. 
Over the last years, a large variety of bioactive compounds has been included in 
microspheres (i.e. antiproliferatives, anti-inflammatories, immunosuppressants, 
antibiotics and even biological therapeutic agents). For the treatment of vitreoretinal 
diseases, microspheres can be administered by intravitreal, periocular or suprachoroidal 
injection (Yasukawa et al., 2004; Herrero-Vanrell et al., 2001; Herrero-Vanrell et al., 
2011a).  
Biodegradable polymers such as gelatin, albumin, polyorthoesters, polyanhydrides 
and polyesters are preferred for the elaboration of microspheres intended for intraocular 
drug delivery, as they disappear from the injection site after delivering the drug (Herrero-
Vanrell et al., 2013). Among them, the derivatives of poly (lactic) acid (PLA), poly 
(glycolic) acid (PGA) and their copolymers poly (lactic-co-glycolic) acid (PLGA) are the 
  
most employed. The U.S. Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) have approved these biopolymers for clinical use. For 
ophthalmic purposes, and especially for the treatment of posterior segment diseases, 
these erodible polymers have been employed to prepare different devices such as 
implants, scleral plugs, pellets, discs, films, and rods (Yasukawa et al., 2004). The 
degradation rate of D- or L-PLA, DL-PLA, and PGA is slower than PLGA, making it 
possible to select the most adequate polymer to prepare the particles. Previous 
experience with these polymers has shown that PLGA 50:50 (50% lactide and 50% 
glycolide) has short in-vivo half-life of degradation (Herrero-Vanrell et al., 2001) and 
degrades relatively fast to metabolic lactic and glycolic acid that are readily eliminated 
from the body after suffering metabolism to carbon dioxide and water mediated by Kreb’s 
cycle (Zimmer and Kreuter, 2005).  
The potential of using biodegradable microspheres in retinal diseases and other 
intraocular pathologies is discussed in this article.  
 
2. Technological aspects of microspheres for intraocular administration 
 
2.1.  Manufacturing of microspheres  
 
There are different methods to prepare microparticles (microcapsules and 
microspheres). They are based on different physico-chemical events: solvent 
extraction/evaporation from an emulsion, aggregation by pH adjustment or heat, 
coacervation (phase separation), interfacial polymerization, ionic gelation and spray 
drying, among others. 
The most common technique for elaboration of microspheres destined to 
intraocular drug delivery is the solvent extraction/evaporation method from an emulsion 
(Freitas et al., 2005). In this technique, the polymer is first dissolved in a volatile solvent 
in which the drug is incorporated (inner phase). Once formed, this discontinuous phase 
is carefully added into a non-miscible solvent also called external phase, including a 
stabilizer to ensure the formation and maintenance of spherical droplets of the inner 
phase in the emulsion (figure 3). Then, the elimination of the dispersed phase solvent is 
performed by extraction/evaporation at room temperature or under vacuum, and as a 
result, solid polymeric microspheres are formed. Finally, the mature microspheres are 
recovered by filtration or centrifugation and dried (lyophillization is preferred because the 
high stability of the final product). Depending on the properties of the active substance, 
the inner phase can form different physico-chemical systems (dissolution, suspension or 
emulsion). In the case of biotechnological products a more sophisticated methodology is 
  
required because of their poor stability of these products during manufacturing (i.e. 
proteins often have large globular structure and exhibit secondary, tertiary and, in some 
cases, quaternary structure that is necessary for biological activity). For these 
macromolecules, water-in-oil-in-water emulsion method (W1/O/W2), in which the protein 
is first dissolved in the inner aqueous phase (W1), is commonly employed. Other 
technological approaches are currently under study for encapsulation of biotechnological 
products. Among them, the inclusion of stabilizers (Freitas et al., 2005) or the use of the 
biotechnological product in its solid state (formation of a solid-in-oil-in-water emulsion; 
S/O/W) (Checa-Casalengua et al., 2011) has shown effective protection of the 
macromolecule. 
 
2.2. Technological properties of microspheres 
 
Once obtained, microspheres are morphologically characterized by using different 
techniques such as optic microscopy and Scanning Electron Microscopy (SEM), among 
others (figure 4). Particle size analysis is carried out by laser diffraction techniques. 
Infrared (IR) spectroscopy helps characterize the polymer and the encapsulated drug. 
Differential scanning calorimetry (DSC) analysis allows establishing the impact of the 
microencapsulation procedure and sterilization on the characteristics of the 
microspheres and possible interactions between the polymer and the encapsulated drug 
(Brittner et al., 1999). One interesting aspect is to evaluate the difference between 
amorphous and crystalline state of the microparticle components performed by X-Ray 
diffraction. Gel permeation chromatography (GPC) is employed to determine the 
molecular weight of formulation components, mainly the polymeric substance. (Herrero-
Vanrell and Refojo, 2001; Martinez-Sancho et al., 2004a; Checa-Casalengua et al., 
2011; Herrero-Vanrell et al., 2013). 
Encapsulation efficiency is a critical parameter and gives the rate between the 
theoretical amount of active substance in the microspheres and the actual amount after 
the microencapsulation procedure. The drug loading in the microspheres is generally 
expressed as micrograms of drug per milligram of microspheres. Both parameters are 
determined using the following mathematical equations: 
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The ability of the microparticulate systems to deliver the drug in a controlled fashion 
is studied by means of in-vitro release experiments. Assays must simulate the in-vivo 
conditions. To do this, particles are suspended in an aqueous solvent (usually PBS, pH 
7.4) in sink conditions. Then, the samples are placed in a shaker bath with constant 
agitation. At fixed time intervals, the supernatant is removed, measuring the drug 
concentration (Herrero-Vanrell et al., 2007). The same volume of fresh medium is 
replaced to continue the release study. Drug release studies can also be assessed by 
dyalisis. This method is especially useful for the release study of poor soluble drugs (He 
et al., 2006). Additives can be employed to modulate the release rate of the active 
substance from the particles. The use of additives in the microparticulate technology will 
be more detailed below.  
 
2.3. Sterilization of microspheres  
 
Microspheres destined to intraocular administration must comply with the sterility 
assurance requirements described in Pharmacopoieas. A final sterilization is preferred 
over preparation of microspheres under aseptic conditions. A sterility assurance level 
(SAL) of 10-6 (statistical probability of finding 1 contaminated unit is 1 million) is generally 
acepted for pharmacopoeial sterilization procedures (Yaman, 2001). 
Among the final available sterilization methods, ethylene oxide, gamma irradiation 
and autoclaving are the most employed. However, their use is limited due to instability 
of the materials (drug and/or polymer) or the production of toxic residues during the 
process. Some of the biopolymers commonly used to prepare microparticles for 
ophthalmic drug delivery, such as PLA and PLGA cannot undergo terminal sterilization 
by steam in a standard autoclave. In the case of thermally sensitive biomaterials, gamma 
irradiation is one of the preferred options because of its high capacity of penetration. The 
gamma irradiation dose required to assure sterilization of a pharmaceutical product is 25 
kGy (Herrero-Vanrell et al., 2001). However, it is well known that γ-radiation can induce 
structural changes in both the polymer (Sintzel et al., 1998) and in the encapsulated 
drug, especially if the active molecule is a protein (Montanari et al., 1998; Jain et al., 
2011). It has been described that irradiation can induce non-desired events such as 
dose-dependent chain scission as well as molecular weight reduction of the polymer, 
affecting the behaviour of the final product (Nijsen et al., 2002). Moreover, in the case of 
proteins, special care must be put on denaturation and degradation processes because 
  
they affect the integrity and bioactivity of the therapeutic agent (Jain et al., 2011). Several 
strategies have been reported to overcome the risk associated to ionizing radiation of 
intraocular microparticulate formulations. The use of low temperatures (dry ice) during 
the sterilization of microspheres loaded with low molecular weight drugs (i.e. acyclovir, 
ganciclovir and celcoxib) has demonstrated to maintain the properties of the formulation 
after gamma irradiation exposure (Herrero-Vanrell et al., 2000; Martinez-Sancho et al., 
2004b; Amrite et al., 2006). However, in the case of microspheres loaded with biological 
products, the use of low temperatures during irradiation does not provide complete 
protection against undesirable reactions (i.e. protein carbonylation and hydroperoxide 
generation) (Sintzel et al., 1998). The use of antioxidants combined with the inclusion of 
the active agent in its solid form has been proposed as a succesful technological strategy 
to promote protein stability during sterilization (Mohanan et al., 2012; Checa-Casalengua 
et al., 2012).  
 
3. Technological strategies to optimize the drug release from microspheres 
 
As therapy must be directed to personalized medicine, the characteristics of the 
formulation must cover the particular requirements of the patient. With this idea, several 
technological approaches have been employed to optimize intraocular microparticulate 
formulations. The inclusion of small molecules or biotechnological products as solids in 
the particles has proven to maintain their stability (Herrero-Vanrell et al., 2000; Checa-
Casalengua et al., 2011). As most of the pathologies affecting the posterior segment are 
multifactorial, the co-encapsulation of two or more active substances results especially 
attractive (Herrero-Vanrell et al., 2009). Several excipients are useful to adjust the 
release of the drug to the therapeutic requirements. They can remain inside the particles 
or be eliminated after manufacturing. Special attention has to be paid in the first case, 
as the substances must be well tolerated. Recently, the use of additives with 
pharmacological properties is one of the most promising approaches to optimize 
intraocular microparticle formulations. 
 
3.1. Hydrophilic additives in microspheres 
 
Hydrophilic additives have been employed to increase the encapsulation efficiency. 
Lysozime as a model protein was encapsulated in biodegradable microspheres and the 
effect of different additives (amphiphilic stabilizer, basic salt and lyoprotectant) was 
evaluated. The highest encapsulation efficiency was observed by using NaHCO3 (15-
94%) although the in-vitro release characteristics were worsened. Cooperative effects in 
  
terms of encapsulation of lysozime were described with the use of rat serum albumin 
(RSA), sucrose and NaHCO3 as additives during the microencapsulation procedure 
(Srinivasan et al., 2005). 
Adjuvants such as polyethylene glycol (PEG 1000), pluronic F68 or gelatin increased the 
drug release rate from PLGA microspheres destined to intravitreal administration. 
Addition of PEG 1000 (30%) or pluronic F68 (3%) accelerated the release of cyclosporine 
(CyS) from PLGA microspheres (Mw 15,000 g/mol; 75:25) prepared by a 
extraction/solvent evaporation method. In this study, pluronic F68 increased the release 
of CyS more significantly and maintained the structural integrity of particles after 2 
months of the release experiment (He et al., 2006). Martinez Sancho et al. (2004a) 
incorporated gelatin in the aqueous phase of the O/W emulsion during the preparation 
of acyclovir loaded PLGA microspheres to produce a higher drug release rate. The 
optimizacion of the formulation was performed applying a two-factor level experimental 
design. The analyzed variables were the amount of the drug included in the formulation 
and the gelatin added to the continuous phase of the emulsion. The best formulation 
according to the results was prepared with a drug:polymer ratio of 2:10 and adding 
gelatin to the aqueous phase (final concentration 0.08%). Microspheres released 
acyclovir at a constant rate for 63 days (1.73  0.08 µg acyclovir/day/mg microspheres). 
Thanks to the addition of gelatin, the optimized formulation reduced by 40% the 
theoretical dosage of microspheres to be administered with respect to initial studies. 
 
3.2. Lipophilic additives in microspheres 
 
Oily compounds have been included as additives in the microspheres to 
modulate the drug release rate. If microparticles are prepared by the solvent 
extraction/evaporation emulsion technique, the lipophilic substance is added to the 
organic phase of the emulsion, remaining inside the particles after maduration. In the 
past decades, our research group has been evaluating the inclusion of oily additives not 
only to control drug release but also to improve the technological properties of 
microspheres. They are able to promote an increase of drug encapsulation efficiency, 
extend the release of the active substances and even protect a biological product from 
degradation (Herrero-Vanrell et al., 1998; Martinez-Sancho et al., 2003; Barcia et al., 
2005; Checa-Casalengua et al., 2011; Checa-Casalengua et al., 2012). 
  
3.3. Additives with pharmacological properties 
 
An additional advantage of using adjuvants is that some of them own 
  
pharmacological properties that make them interesting in the ophthalmic therapy. This is 
the case of retinoic acid (vitamin A) and the vitamin E with antiproliferative and 
antioxidant properties that have already been included in the microspheres. Inclusion of 
Vitamin A in acyclovir PLGA 50:50 microspheres resulted in a more prolonged release 
of the drug (Martinez-Sancho et al., 2006). In the case of biological products, vitamin E 
was used in combination with the Glial Cell-line Derived Neurotrophic Factor (GDNF) 
(Checa-Casalengua et al., 2011) for glaucoma treatment. Under the technological point 
of view, the addition of vitamin E increased the encapsulation efficiency of GDNF, 
protected the biotechnological product from degradation and extended the release of the 
active substance.  
 
4. Syringeability and injectability of microspheres 
 
 Syringeability and injectability are key-product performance parameters of 
intraocular dosage forms. The former refers to the ability of an injectable therapeutic to 
pass easily through a hypodermic needle or transfer from a vial prior to an injection, while 
the latter is related to the performance of the intraocular formulation during injection.  
Properly syringeability and injectability assures to administer the prescribed dose of the 
active substance. Microspheres are injected as a conventional suspension so special 
care must be taken in the preparation of homogenous particle dispersion in the clinical 
practice. Injectability studies of microsphere suspensions are directed to select the 
optimal diameter and length of needles, by calculating the force recorded to inject the 
selected concentration of particles. The application of a maximum ejection force of 12 
Nw over 10 seconds is considered suitable for a proper injection. The vehicles used to 
resuspend microspheres can influence the time of particle precipitation. BSS or isotonic 
phosphate buffer solutions pH 7.4 are mainly used as vehicles.  Solutions composed of 
viscosity enhancers can also be employed to delay the clumping of particles. If 
microspheres clogging occurs, biopolymers such as hydroxypropylmethylcellulose or 
hyaluronic acid added in the aqueous vehicle help improve both syringeability and 
injectability (Herrero-Vanrell and Refojo, 2001; Gomes do Santos et al., 2006). These 
pseudoplastic polymers are commonly used as surgical aids in ophthalmology. 
Moreover, these polymeric solutions are transparent and biocompatible, being rapidly 
diluted in the intraocular fluids and eliminated from the eye (Chan et al., 1984; Herrero-
Vanrell et al., 2001). 
 Rojas et al. (2013) analyzed the influence of the time elapsed between the 
preparation of the microsphere suspension and the injection on the clumpling of 
polyesteramide derivative particles for intraocular administration. With this objective, 
  
suspension of particles were released through different needles gauges (25G, 27G, 30G 
and 32G) and quantified in a Nebauer chamber cell counting. According to authors, the 
clumping of the particles had a clear relation with the time, being greater at 30 minutes 
after suspension preparation. No significant differences were observed in the amount of 
microspheres released through the different needle gauges. Martinez- Sancho et al. 
(2004a) evaluated the injectability of sterilized acyclovir PLGA 50:50 microparticles 
(15,000 g/mol) (20-40 μm) by injecting them through different gauge needles (27G, 25G, 
and 21G) employed in the clinical practice. The results of syringeability indicated neither 
partial nor complete blockage of the suspension flow. Authors concluded that these 
microspheres were suitable for intraocular injection through a 27-gauge needle. 
Suprachoroidal administration of microspheres requires more sophisticated technology. 
Patel et al. (2011), have evaluated the use of microneedles for suprachoriodal injection 
of nanoparticles (20-1000 nm) and microparticles (10 μm). These devices penetrate only 
a few hundred micrometers into the sclera (Patel et al., 2012). Parameters such as 
microneedle length, pressure and particle size are critical parameters to render optimal 
delivery into the suprachoroidal space. 
 
5. Determination of the amount of microspheres for injection 
 
The amount of microspheres to inject for the treatment of vitreoretinal diseases 
depends on the therapeutic window of the drug, its intravitreal pharmacokinetic as well 
as on the drug payload in the particles and its release kinetic (Barcia et al., 2009). 
Theoretically, the amount of microspheres (A) to be intravitreally administered can be 
calculated through the following pharmacokinetic equation:    
A×K0 = Css ×Cl 
Where Css is the steady state concentration of the drug in the vitreous that must be 
achieved and maintained for therapeutic efficacy. Cl is the drug clearance in the vitreous. 
Cl is a product of Ke (drug elimination constant in the vitreous) and Vd (vitreous 
distribution volume). K0 is the theoretical zero-order drug release rate per mg of 
microspheres.  
If microspheres are administered by another route different than the direct deposit of 
the formulation in the vitreous cavity, the amount of microspheres for injection can be 
calculated by using pharmacokinetic modelling. In this case, different ocular tissues 
(sclera, choroid, retinal pigment epithelium and vitreous) must be introduced in the 
equation, also taking into account the clearance of the active substance via choroidal 
circulation (Ranta and Urtti, 2006).  
 
  
6. Tolerance of microparticles for intraocular administration 
 
Tolerance studies for microspheres can be performed in-vitro and in-vivo (both in 
animals and humans). 
 
 6.1. In-vitro tolerance studies 
 
In-vitro tolerance studies give preliminary information about the response of cells to 
formulations and avoid the use of experimental animals in the first stages of a 
pharmaceutical product development. Immortalized retinal pigment epithelial cell lines  
and primary cultures of retinal cells are the most employed in formulations destined to 
intravitreal administration (Szurman et al., 2009). Other cells lines with high sensitivity 
are also used to test tolerance of ophthalmic formulations. This is the case of peritoneal 
macrophages used to study the in-vitro tolerance of polymers and microspheres for 
intraocular drug delivery (Andrés-Guerrero et al., 2013). Recently, ex-vivo models of 
retinal diseases have been used to test tolerance of polymers and particles (Arango-
Gonzalez et al., 2013). 
 
6.2. Tolerance studies in animals 
 
Local administration of microparticles involves mainly intravitreal and periocular 
(sub-Tenon, subconjuntival and posterior juxtaescleral) injections (Herrero-Vanrell et al., 
2001; Kompella et al., 2003; Amrite and Kompella, 2005; Ranta and Urtti, 2006; Barcia 
et al., 2009, Checa-Casalengua et al., 2011). Suprachoroidal administration using 
microneedles has been also performed (Patel et al., 2011; 2012) (figure 5). 
The injection volumes usually reported are between 50-100 μL (Herrero-Vanrell et 
al., 2013), although higher quantities can be accommodated in periocular spaces. The 
toxicity and biocompatibility of the PLGA drug delivery systems have been evaluated 
after injection. In-vivo ocular tolerance of drug delivery systems depends mainly on their 
composition and site of administration.  
 
6.2.1. Intravitreal administration 
 
Several reactions have been described after intraocular administration of PLGA 
microspheres. The most frequent is the tendency of particles to aggregate by forming a 
whitish depot (Khooebi et al., 1991). The permanence of the aggregate is variable as the 
  
polymer takes different times to degrade. By histological studies, a mild localized foreign 
body reaction was described after the administration of ganciclovir-loaded microparticles 
in rabbits. In the same study, histopathologic analysis at 4 and 8 weeks post-injection 
showed mononuclear cells and multinucleated giant cells surrounding the particles, with 
no involvement of the retina or other ocular structures (Veloso et al., 1997). The studies 
showed minimal focal disruption of the retinal architecture in eyes receiving both 
ganciclovir-loaded and blank microspheres. In general, the foreign body response is 
associated with the type of polymer and decreased with time. Particles remained at the 
implantation site and, according to some authors, twelve weeks after injection in rabbit 
eyes only pieces of microparticles could be recognized remaining at the injection site 
(Visscher et al., 1985; Moritera et al., 1992).  
Among the clinical signs, inflammation is the most frequently described after 
intravitreal injection of PLGA microparticles in rabbits. This reaction is similar to the one 
reported for sutures made of PLGA and after intramuscular injection of particles in rabbits 
(Visscher et al., 1985). Inflammation signs were associated to early stages after injection 
and disappeared 2-4 weeks after administration. In any case, no retinal and choroidal 
damage were observed 35 days after administration (Giordano et al., 1995).  
 
6.2.2. Periocular administration  
 
 No inflammatory reaction in the retina nor surrounding tissues has been associated 
to PLGA microspheres after periocular injection. Mild conjunctival congestion is the most 
frequent clinical sign reported. Periocular route allows higher amounts of particles in the 
injection site than intraviteral administration without noticeable adverse signs.  Periocular 
injection in pigs of 100 mg of blank microspheres (42.5 μm) or microspheres containing 
25% or 50% of the kinase inhibitor PKC412 (67.7 μm) caused mild conjunctival reaction 
that was similar among the three groups. There were no discernible signs of inflammation 
or irritation. Ten days after injection the microspheres appeared as bulges beneath the 
conjunctiva (Saishin et al., 2003). Similarly, administration of PLGA microspheres loaded 
with celecoxib did not produce signs of inflammation 60 days after administration. 
Furthermore, no significant changes were observed in the thickness of retinal layers 
between untreated rats and animals receiving the celecoxib microparticles. Visual 
inspection of the site of action (periocular tissue) did not reveal the presence of 
inflammation, including redness and edema (Amrite et. al, 2006). In case of rabbits, no 
adverse signs were observed after juxtaescleral injection of 5 mg of PLGA particles 
(blank and loaded with dexamethasone) suspended in BSS. Authors reported only 
  
conjunctival congestion at the administration site (24 h and 2 weeks post-injection for 
unloaded microspheres and 24 h and 1 week for dexamethasone-loaded microspheres) 
and concluded that PLGA microparticles are suitable for juxtascleral injection in rabbits 
with no adverse affects (Herrero-Vanrell et al., 2010a). 
In terms of intraocular tolerance, the nature of the polymer is critical. Furthermore, 
the biological response to a biomaterial depends on the physiological nature of the 
tissue. Rincon et al. (2005) evaluated the response to microparticles prepared from an 
elastin derivative poly (valine-proline-alanine-valine-guanine) (VPAVG) in different 
tissues. The authors reported no inflammatory response after subcutaneous injection of 
different amounts of particles (1.5 mg and 2.5 mg) in the hind-paw of the rat. Similar 
results regarding to the absence of inflammation were reported after intravitreal injection 
of 2.5 mg of poly (VPAVG) microparticles in which a few rabbits of the experimental 
group presented inflammation signs (2/11). However, at the end of the study (28 days 
after injection) 45% (5/11) of the animals showed tractional retinal detachment. This 
adverse effect was related to certain fibroblastic activity induced by the polymer. These 
results confirm the importance of testing tolerance in the specific ocular site. 
 
6.2.3 Suprachoroidal administration 
Nanoparticles (20 nm and 500 nm) and microparticles (1 μm and 10 μm) of 
fluospheres were administered into the space located between the sclera and choroids 
(Patel et al., 2012). The fundus of the injected rabbit eyes appeared normal with no 
inflammation or abnormalities as compared with uninjected eyes. 
6.3. Tolerance studies in humans 
 
6.3.1. Intravitreal administration 
 
Cardillo et al. in 2006 reported a preliminary study of the potential use of PLGA 
microspheres for the treatment of macular edema. Intravitreal sustained-release 
triamcinolone microspheres system (RETAAC) was injected in human eyes. In this study, 
authors reported a good tolerance for the particles after their intravitreal injection. 
Although special concern is related to the risk of visual-impairment after intravitreous 
injection of microparticles, this preliminary investigation in humans has shown the 
opposite. The tendency of the microspheres to aggregate and condensate at the site of 
the injection leaving a free visual axis was reported after clinical evaluation in patients 
receiving the treatment. No inflammation signs were reported although it should be taken 
into account that, in this case, the anti-inflammatory substance could attenuate the 
inflammatory reaction.  
  
 
6.3.2. Periocular administration 
 
Paganelly et al. (2009) injected periocularly 2 mg of PLGA (50:50) microspheres (mean 
size 1.07 ± 0.35 µm) loaded with cyprofloxacin (0.99 mg) in a combination of a solution 
of 25 mg of triamcinolone acetonide in humans. The combined treatment was compared 
with the topical administration of prednisolone (1%) and ciprofloxacin (3%) eye drops 
during 4 weeks. The safety of both treatments was evaluated (intraocular pressure, 
biomicroscopy, and ophthalmoscopic findings) resulting in the same ocular tolerance for 
both pharmacological therapies after cataract surgery. 
 
 
7. Movement of particles after injection 
 
The movement of particles after intravitreal and periocular injection has been studied 
in different animal models and humans. 
 
7.1. Intravitreal  administration 
 
PLGA microparticles are not expected to move as they have the tendency to 
aggregate several days after their intravitreal injection, which has been previously 
observed in animals and humans (Giordano et al., 1995; Herrero-Vanrell et al., 2001., 
Cardillo et al., 2006; Barcia et al.,2009) (figure 6). In the case of intravitreal injection, the 
influence of the presence and absence of the lens on the movement of microspheres 
has been described in rabbits. Intravitreous injected microparticles (7-10 micrometer 
size) were retained in the vitreous cavity in phakic eyes while some particles moved to 
the anterior chamber in aphakic eyes (Algvere and Bill 1979). 
 
7.2. Periocular administration 
 
In the case of periocular injection, the size of particles affects their ocular distribution. 
After subconjunctival injection in rats, fluorescent polystyrene particles in the nano- size 
(20 and 200 nm) and micro-range (2 μm) behaved differently depending on their size. 
While particles higher than 200 nm were retained in the site of injection up to 60 days, 
lower sizes were able to move across the sclera and were rapidly cleared by the systemic 
and lymphatic circulation (Amrite and Kompella, 2005).  
 
  
8. Degradation of PLA and PLGA microspheres 
 
PLGA is amorphous and, in general terms, its degradation rate is faster than the one 
observed for the more crystalline PLA polymer. For example, the 50:50 PLGA has 
shorter half-life than the 75:25 PLGA, and this one degrades faster than PLA (Li, 1999). 
The degradation of these polymers takes place by hydrolysis of its ester linkages in the 
presence of water (Giordano et al., 1995).  Among the polymers with the same 
composition, the lower molecular weight of the polymers and copolymers the faster the 
degradation rate (Herrero-Vanrell and Refojo, 2001). 
 
8.1. In-vitro degradation of microspheres 
Degradation of microspheres depends on the polymer properties, the possible 
interaction among components and on the characteristics of the microparticles. Moritera 
et al. (1991) demonstrated the influence of polymer composition and molecular weight 
of PLA and PLGA polymers on the release rate (in-vitro and in-vivo) of microspheres (50 
μm) loaded with 5-fluorouracil (5-FU). Not surprinsingly, PLGA (3,300 g/mol) 
microspheres showed a faster in-vitro release (98% of the encapsulated drug) in only 2 
days, while the 3,400 g/mol and 4,700 g/mol PLA particles took almost 7 days to release 
85% and 70% of the 5-FU, respectively. It is interesting to note that the presence of the 
drug may affect degradation time of the particles (Visscher et al., 1985; Maulding et al., 
1991). The influence of the acidic or basic properties of the active substance 
encapsulated in the microparticles in the enhancement of the hydrolytic degradation of 
the polymers has been reported (Delgado et al., 1996; Li 1999). Morphology change 
studies in microspheres have been performed during the in-vitro release assays. Checa-
Casalengua et al. (2011) observed no changes in the morphology of GDNF loaded 
microspheres after 2 weeks of the release study. However, surface erosion of the 
particles appeared at 4 weeks. The erosion resulted more evident and particles began 
to aggregate after 6 weeks of in-vitro incubation, being completed after 8 weeks of the 
assay (figure 7). 
 
8.2. In-vivo degradation of microspheres 
 
Degradation of erodible microparticle systems after injection depends on their 
characteristics (i.e. size, structure, drug loading) as well as on the polymer properties. 
The amount and the size (total surface area) of the microspheres also govern the 
degradation rate. Smaller size microparticles degrade faster than larger sizes (Herrero-
Vanrell et al., 2001; Grizzi et al., 1995). As mentioned previously, experience has 
  
demonstrated that the PLA and PLGA polymers suffer biodegradation. The rate of 
polymer biodegradation (in-vitro and in-vivo) depends on PLA:PGA ratio and molecular 
weight of the polymer (higher molecular weights degrade slower than low molecular 
weight polymers) (Miller et al., 1977). Furthermore, surgery procedures have shown to 
accelerate microparticle clearance. As an example, Moritera et al. (1991) studied the 
influence of vitrectomy in rabbits. Clearance from the vitreous cavity was accelerated in 
animals that underwent vitrectomy. According to authors, particles gradually reduced 
their size faster in vitrectomized eyes.  On the other hand, when Giordano et al. (1995) 
evaluated the biodegradation and clearance time of unloaded microspheres of a 
relatively low molecular weight polymer (inherent viscosity 0.2 dL/g) from the vitreous 
cavity in rabbits after gas vitrectomy, they found evidence of the microparticles up to 24 
weeks postinjection. 
 
 
9. Microspheres as therapeutical tools for the treatment of vitreoretinal 
diseases 
 
 
Microspheres intended for the treatment of posterior segment diseases have been 
injected by periocular or intravitreal route. Although several studies have been conducted 
employing the topical route, there is no evidence yet of effective drug concentrations in 
the vitreous after this administration route. 
Depending on their potential use, PLGA microparticles have been loaded with 
different drugs. Microspheres destined to the treatment of proliferative retinopathy have 
been prepared with adriamycin and retinoic acid, anti-inflammatory and 
immunosuppressants (dexamethasone and cyclosporine) were tested for uveitis, 
budesonide and celecoxib for diabetic retinopathy, triamcionolone acetonide for macular 
edema, acyclovir for herpes infection, ganciclovir for cytomegalovirus retinitis, 
neurotrophic factors such as GDNF for neuroprotection in glaucoma, anti-endothelial 
growth factor agent (anti-VEGF) for age-related macular degeneration (AMD),  
tauroursodeoxycholic acid (TUDCA) for photoreceptor rescue in retinitis pigmentosa, the 
protein kinase C (PKC412) inhibitor for choroidal neovascularization (CNV), a 
combination of steroids (triamcinolone) and antibiotic agents (cyprofloxacin) to prevent 
ocular inflammation and infection after cataract surgery and antisense TGF-β2 
phosphorothioate oligonucleotides to prevent post-surgical fibrosis. 
 
9.1. Proliferative Vitreoretinopathy (PVR) 
 
Microparticles intended for the treatment of PVR have been loaded with different 
  
drugs with antiproliferative activity (Moritera et al. 1991; 1992).  
Low molecular weight PLA (3,400 g/mol) microspheres (50 µm size) loaded with 
adryamicine (1%) were intravitreally administered in a rabbit model of PVR and in healthy 
animals. The study tried to compare the administration of the active substance in solution 
with a long-term release of the drug (Moritera et al., 1991). Suspensions of microspheres 
(10 mg and 3 mg) were injected. A decrease of retinal detachment (RD) from 50% to 
10% in PVR was observed in rabbits 4 weeks after administration of 10 mg of 
adryamicine-PLGA microspheres. On the contrary, 3 mg of PLA microspheres containing 
3 μg of adryamicine was not able to decrease the rate of retinal detachment. Authors 
found a significant decrease in retinal toxicity of the injection of microspheres in 
comparison with the administration of the same amount of drug in solution with neither 
histological abnormalities nor electrophysiological changes in the treated eyes. The 
same authors observed a faster clearance of the drug and the microspheres in pathologic 
eyes compared with healthy eyes.  
Giordano et al. (1993) studied the intravitreous release of retinoic acid (RA) in a 
rabbit model of PVR caused by a lipopolysaccharide (LPS) injection. Microspheres 
released the drug in-vitro for 40 days. In-vivo studies showed that the incidence of 
tractional detachment 2 months after the administration of 5 mg of RA-loaded 
microspheres with a dose of 110 μg of RA was effectively reduced when compared to 
blank microspheres.  
 
9.2. Uveitis 
 
 The term “uveitis” is used to denote any intraocular inﬂammatory condition without 
reference to the underlying cause (Rodriguez et al., 1996). Corticosteroids have proven 
efficient anti-inflammatory activity for the treatment of acute ocular inflammations such 
as uveitis. Intravitreal injections of steroids provide therapeutic drug levels (Gaudio, 
2004) but only for short periods of time. Due to the short half-life of corticosteroids the 
maintenance of effective intravitreal concentrations in the target site is difficult to attain 
(Kwak and D´Amico, 1992). 
Barcia et al. (2009) developed dexamethasone-PLGA microspheres (53 μm) for 
intravitreal administration to prevent intraocular inflammation in an animal model of 
uveitis. To this, 10 mg of PLGA 50:50 (0.2 dL/g) microspheres containing 141 µg of 
dexamethasone/mg microspheres were suspended in 0.1 mL of isotonized PBS and 
injected in an animal model of inflammation. One week before the administration of 
particles a lipopolysaccharide (LPS) injection was performed. At one day and one week 
after microsphere injection, the intraocular inflammation caused by LPS injection 
  
resulted significantly lower in treated animals compared to the group receiving blank 
particles. In the same study, a second injection of LPS was performed to simulate 
secondary uveitis (30 days after microspheres injection). No inflammation signs were 
observed in the animals treated with PLGA microspheres loaded with the anti-
inflammatory agent after a second LPS injection, demonstrating that an effective 
concentration of the drug was still present. He et al. (2006) prepared cyclosporine (CyS) 
PLGA (75:25) of low molecular weight (15,000 g/mol) microparticles (50 μm) intended to 
treat uveitis and other intraocular immune disorders. Microparticle formulations 
maintained sustained therapeutic concentrations of CyS for at least 65 days in the 
choroid-retina and iris-ciliary body of healthy rabbits. The mean residence time of the 
drug included in the microspheres resulted 10 times higher than the CyS administered 
in solution. 
 
9.3. Diabetic Rethinopathy (DR) 
 
The evaluation of microparticulate carriers loaded with budesonide and celecoxib 
has been assayed for the treatment of diabetic retinopathy. Comparison between nano- 
(50 μg) and microparticles (75 μg), loaded with budesonide were performed after 
subconjunctival injection of particles in rats. In this study, microparticles (3.60  0.01 µm) 
delivered the active substance in a more sustained fashion than nanoparticles (345  2 
nm) (Kompella et al., 2003). According to authors the nanosystems were removed more 
rapidly from the subconjunctival site of administration than microparticles. Nanoparticles, 
microparticles and budesonide in solution (75 µg) were administered in rat eyes. Different 
tissue levels (retina, vitreous, lens and cornea) were compared at different times after 
administration. On day 7 and 14 drug levels in the eyes treated with microspheres 
resulted higher compared with the solution and nanoparticles. Sustained release of 
celecoxib from PLGA (85:15) microspheres (1.11  0.08 μm) was evaluated in a diabetic 
rat model (Amrite et al., 2006). A posterior subconjunctival injection of 0.05 mL of 
celecoxib-microsphere suspension (14.93% ± 0.21%) was usuful to inhibit diabetes-
induced elevations in PEG2, VEGF and blood-retinal barrier leakage. 
 
9.4 Macular edema (ME) 
 
Macular edema (ME) is frequently treated with corticosteroids. Among them, 
triamcinolone is the most used.  
 
9.4.1 Intravitreal administration 
  
 
As previously cited, one of the first evaluations of PLGA microspheres in humans 
has been performed in patients suffering diffusse macular edema (Cardillo et al., 2006). 
Eyes treated with triamcinolone-loaded microspheres and showed marked decrease of 
retinal thickness as well as improved visual acuity for 12 months.  
 
9.4.2 Periocular administration 
 
Microspheres loaded with betamethasone appear under phase II/III clinical trial for 
the treatment of diabetic macular edema (Yasukawa et al., 2011). The microspheres are 
intended for sub-Tenon injection. 
  
9.5 Acute Retinal Necrosis (ARN) 
 
Viral infection is related to necrosis of retinal cells that can lead to irreversible 
blindness. Therapy for ARN usually involves intravenous or intravitreal administration of 
acyclovir. Although intravitreal administration of acyclovir has demonstrated to be more 
effective than the intravenous administration of the drug with fewer side effects, the 
relatively high dose required has untoward effects. Conte et al. (1997) developed 
controlled release microparticles from PLA and PLGA polymers. Particles were loaded 
with acyclovir using the spray-drying technique. The formulations were tested as an 
alternative to intravenous or intravitreous administration of the drug in solution in the 
treatment of acute retinal necrosis caused by virus injection. The drug was detected in 
the rabbit vitreous for 14 days after injection of D,L-PLA (28,000 g/mol) microparticles 
(0.5 mg) of 25 m. Chowdhury and Mitra (2000) have described guanosine-loaded PLGA 
(75,000–100,000 g/mol) microspheres developed for a drug release of 1 week after 
intravitreal injection of the particles.  
 
9.6 Cytomegalovirus retinitis (CMV) 
 
CMV retinitis occurs in immunodeficiency patients and its progression can result 
in blindness from retinal detachment associated with retinal necrosis (Jab et al., 1989; 
Henry et al., 1987). Although intravitreal ganciclovir injections provide effective 
intraocular drug concentrations, frequent injections are required to maintain therapeutic 
drug levels.  
 
  
With the objective to avoid frequent injections, Veloso et al. (1997) tested the 
antiviral effect of ganciclovir released from PLGA microspheres (300-500 μm) in rabbit 
eyes inoculated with the human cytomegalovirus (HCMV). Injection of ganciclovir-loaded 
microspheres (10 mg) prepared from PLGA 50:50 (inherent viscosity 0.39 dL/g) with 86.4 
µg of ganciclovir/mg microspheres, controlled the progression of the disease in the 
HCMV-inoculated rabbit eyes. In treated eyes, vitritis, retinitis and optic neuritis 
decreased during the 14 days of the study, in contrast with control eyes. 
Immunofluorescence of virus antigen was not observed in treated eyes. Duvvuri et al. 
(2007) injected PLGA (different ratios of lactic: glycolic acid) microspheres prepared with 
ganciclovir and dispersed in a thermogelling solution of PLGA-PEG-PLGA in rabbit eyes. 
60 μL of the microparticle formulation (196 μg of ganciclovir) was administered in rabbits. 
The formulation maintained mean vitreal concentrations of ganciclovir at approximately 
0.8 μg/mL for 14 days, whereas direct injections maintained drug levels above 0.8 μg/mL 
for only 54 hours. 
 
9.7. Choroidal Neovascularization (CNV) 
 
PLGA microspheres loaded with a kinase inhibitor PKC412 were periocularly 
injected in a porcine model of laser induced choroidal neovascularisation (CNV) obtained 
by laser photocoagulation (Saishin et al., 2003). After the rupture of Bruch’s membrane 
in eight locations, 100 mg of microspheres were injected in the animals. Microspheres 
loaded with different amounts of PCK412 (25 or 50%) were compared to blank 
microspheres. After 10 days, the areas of CNV at Bruch’s membrane rupture sites were 
noticeable lower for PCK412 microspheres. PCK412 levels in vitreous, retina and 
choroids were detected 20 days after periocular injection for the 50% PCK412 loaded 
microparticles. 
 
9.8. Degenerative diseases affecting the optic nerve. Glaucoma. 
 
Neuroprotection has been proposed as a therapeutic option for the treatment of 
glaucoma. The therapeutic approach focuses on promoting the survival of retinal 
ganglion cells (RGC) which can be achieved by the local sustained delivery of 
neurotrophic factors such as Glial cell line-Derived Neurotrophic Factor (GDNF). Jiang 
et al. (2007) investigated the potential of GDNF-loaded microspheres using the 
hypertonic saline model. In this work microspheres remain in the vitreous for at least six 
weeks. At 8 weeks following a second hypertonic saline injection, in retinas treated with 
  
GDNF microspheres, the authors reported a decrease in nerve head cupping and an 
increase in the thickness of nerve fiber and inner plexiform layers. Xiao and Zhang, 
(2010) described a significant increased long-term retinal ganglion cell survival in the 
DBA/2J mouse glaucoma model after injection of microspheres loaded with GDNF. 
Checa-Casalengua et al. (2011) evaluated the efficacy of long-term delivery of low 
amounts of GDNF in an animal model of glaucoma. Microspheres were prepared from 
PLGA 50:50 (Mw 35,000 g/mol) and GDNF combined with vitamin E (vit E). The effects 
of GDNF/VitE microspheres on RGC survival were evaluated 10 weeks after injection by 
counting anti-NeuN positive cells in the ganglion cell layer (GCL) (figure 8). In eyes 
without IOP elevation, the average number of anti-NeuN positive cells were 67.4  
4.2/mm. After ten weeks of IOP elevation, a significant loss of the RGC (20.8  2.1/mm) 
was observed for blank particles. GDNF/Vit E microspheres (0.64 ng GDNF/eye) 
resulted in a preservation of RGC (51.6  3.2/mm). The positive effect of the novel 
GDNF/VitE formulation on the optic nerve axon survival was also demonstrated after 
comparing the number of axons in elevated IOP eyes compared to the number of axons 
in the contralateral eye without IOP elevation. The survival percentaje resulted 
significantly higher (72.68%) for GDNF/VitE microspheres compared to GDNF (36.58%), 
Vit E (30.65%) and blank microspheres (28.96%) groups. The neurotrophic factor in 
combination with Vit E released from the microspheres was effective for at least 10 
weeks after a single intravitreal injection in an animal model of glaucoma. These results 
confirm the hypothesis that low amounts of GDNF maintained for a long time resulted 
effective in a chronic degenerative disease such as glaucoma. 
 
9.9. Photoreceptors degeneration. Retinitis pigmentosa (RP). 
 
Retinitis pigmentosa is an inherited disease that brings on retinal degeneration. This 
degenerative pathology causes vision impairment and often blindness. Patients undergo 
a gradual loss in vision because of the death of the rods and cones. 
Systemic high dose of tauroursodeoxycholic acid (TUDCA) has demonstrated to 
prevent degeneration of photoreceptors in rd10 mice and P23H rat retina. PLGA 
microspheres (2-40 μm) loaded with TUDCA (drug: polymer ratio 2:10) were intravitreally 
injected in homozygous P23H line 20 days old rats. Rats received phosphate buffer 
solution (5% w/v) in the right eyes as control. Retinal function was assessed by 
electroretinogram at P80, P100 and P120. Scotopic a- and b-wave amplitudes were 
analyzed. Scotopic light-induced retinal responses registered at P80 showed a- and b-
wave mean amplitudes significantly higher in TUDCA-PLGA injected eyes compared 
with vehicle-injected. Maximal differences were observed at the maximal amplitude 
  
responses both in a- and b-waves. Significant differences in a- and b-wave amplitudes 
were not found at P100 and P120. This work suggested that PLGA microspheres loaded 
with TUDCA have a potential neuroprotective effect that could be useful to delay vision 
loss in retinitis pigmentosa (Herrero-Vanrell et al, 2011c). 
Andrieu-Soler et al. (2005) developed PLGA microspheres loaded with 
recombinant human glial cell line-derived neurotrophic factor (rhGDNF). The particles 
controlled the release of the biotechnological product (10 ng/day) for 3 months and 
resulted efficient preventing retinal degeneration in an animal model of retinosis (rd1) for 
17 days. A significant delay of rod photoreceptor degeneration was observed in mice 
receiving the rhGDNF-loaded microspheres compared to either untreated mice or mice 
receiving blank or inactivated rhGDNF microspheres. 
 
9.10. Age-Related Macular Degeneration (AMD) 
 
Therapeutic angiogenesis via local delivery of protein drugs is one of the 
approaches to treat exudated age related macular degeneration. Anti-vascular 
endothelial growth factors (bevacizumab, ranibizumab and aflibercept) have been 
employed to reduce the neovascularisation in the eye (van Wijngaarden et al., 2008). 
Carrasquillo et al. (2003) prepared PLGA microspheres containing anti-vascular 
endothelial growth factor (anti-VEGF) RNA aptamer. The biotechnological product was 
encapsulated after freeze-drying with and without trehalose. In these conditions the 
inhibition showed by the aptamer was, in general, enhanced when it was co-lyophilized 
with trehalose. The microspheres released the aptamer in an average rate of 2 μg/day. 
The particles were loaded into a device and placed on the sclera of Dutch belted rabbits. 
The feasibility of delivering the bioactive anti-VEGF aptamer in a controlled manner was 
demonstrated. 
 
9.11. Prevention of intraocular inflammation, infection and post-surgical fibrosis after 
cataract surgery 
 
Ocular inflammation and infection after cataract surgery can be prevented with a 
co-administration of steroids and antibiotic agents. A treatment including PLGA 
ciprofloxacin-loaded microspheres and a solution of triamcinolone was compared with 
the topical administration of prednisolone (1%) and ciprofloxacin (3%). Efficacy of both 
treatmens was evaluated after 4 weeks (anterior chamber, cell and flare, conjunctival 
erythema, ciliary flush or symptons of ocular inflammation). The authors stated the same 
therapeutic response with both pharmacological therapies after cataract surgery 
  
(Paganelli et al., 2009). 
Gomes do Santos et al. (2006) prepared nanosized complexes of antisense TGF-β2 
phosphorothioate oligonucleotides encapsulated in PLGA microspheres. The authors 
called the microparticulate systems “Trojan” microspheres. A suspension of 4-5mg of 
microspheres in 100 µL of a viscosizing agent (sodium hyaluronate 1.35%) was 
administered by subconjuctival injection in a rabbit experimental model of filtering 
glaucoma surgery. The authors described a prevention of post-surgical fibrosis following 
trabeculectomy for 42 days.  
 
9.12. Microspheres for Regenerative Medicine. Co-trasplantation of microspheres with 
Retinal Progenitor Cells (RGCs). 
 
Failure of the adult mammalian retina to regenerate can be partly attributed to the 
barrier formed by inhibitory extracellular matrix (ECM) and cell adhesion molecules, such 
as CD44 and neurocan. After degeneration, this mentioned barrier separates a subretinal 
graft from integrating into the host retina. Matrix metalloproteinase 2 (MMP2) can 
promote host-donor integration by degrading these molecules. Retinal combination of 
PLGA microspheres loaded with MMP2 and retinal progenitor cells (RPCs) have been 
assayed to enhance cellular integration and promote retinal repopulation (Yao et al., 
2010). To this purpose, PLGA microspheres (2-20 µm) loaded with MMP2 and RPCs 
were co-transplanted to the subretinal space of adult retinal degenerative Rho−/− mice. 
Highly porous microspheres loaded with MMP2 were prepared, as fast release of the 
bioactive agent was needed. Following the delivery of MMP2 from microspheres, 
significant degradation of CD44 and neurocan at the outer surface of the degenerative 
retina without disruption of the host retinal architecture was observed. Furthermore, no 
changes in the differentiation characteristics of RPCs were shown due to the 
microspheres. The results suggest the co-transplantation of MMP2 microspheres and 
RPCs as a practical and effective strategy for retinal repair. 
 
10. Current and future developments 
 
Local administration of microparticulate systems can be considered as a therapeutic 
strategy to overcome the limitation of systemically administered drugs. The main goal in 
the development of microparticles for the treatment of retinal diseases and other 
intraocular pathologies has been to obtain long-acting injectable drug formulations and 
specific targeting options of the therapeutic molecule. Biodegradable microspheres 
represent an effective alternative to repeated intraocular injections. Administration of 
  
microparticles is performed easily after their suspension in an aqueous vehicle. Injection 
of microparticles is performed without the need for surgical procedures. As most of the 
diseases affecting the back of the eye are chronical and multifactorial, microspheres are 
especially promising in this field. They can be loaded with more than one active 
substance and complemented with the inclusion of additives with pharmacological 
properties. Personalized therapy can be easily achieved by changing the amount of 
administered microspheres. After injection, PLA and PLGA microspheres suffer 
aggregation, behaving like an implant. Contrary to the non-biodegradable devices, PLA 
and PLGA microspheres disappear from the site of administration after delivering the 
drug. Furthermore, microspheres prepared from the aforementioned biomaterials are 
well tolerated after periocular and intravitreal injections in animals and humans. 
Biodegradable microspheres are also potential tools in regenerative medicine for retinal 
repair. According to the results reported, presumably a variety of microparticulate 
formulations for different ophthalmic therapeutic uses will be available in the clinical 
practice in the near future. 
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FIGURE CAPTIONS 
  
 
 
Figure 1. Strategies to avoid frequent intraocular administrations. Drug delivery systems: 
biodegradable and non-biodegradable implants and biodegradable microspheres.  
 
Figure 2. Structure of microparticles (microspheres and microcapsules). In the 
microspheres, the active substance is dispersed in a polymeric network (matrix system), 
while microcapsules are formed by a core containing the drug, which is surrounded by a 
layer composed of a polymer or a mixture of several polymers (reservoir system).  
 
Figure 3. According to the solvent extraction/evaporation method, microparticles are 
prepared from O/W, W/O/W or S/O/W emulsions. O/W: The polymer is first 
dissolved in a volatile solvent in which the drug is incorporated. This solution is 
then emulsified with a non-miscible solvent to form microparticles. W/O/W: A first 
emulsion (W1/O) is formed between anadjuvant aqueous solution of the active 
substance and an organic polymeric solution. A second emulsion (W1/O/W2) is 
then prepared by the addition of the W1/O emulsion to an aqueous external 
phase. S/O/W: The active substance in solid state is dispersed in an organic 
polymeric solution (S/O) and then added to an aqueous external phase to form 
microparticles. In all cases, microparticles are formed in the presence of an 
emulgent to ensure their formation and maintenance during the process. After 
the organic solvent removal, mature particles are recovered by filtration and 
dried. 
 
 
Figure 4. PLGA (50:50, Resomer 502) microspheres loaded with dexamethasone 
prepared by a solvent extraction/evaporation method from an O/W emulsion. 
 
Figure 5. Local administration of microspheres for the treatment of retinal and other 
intraocular diseases: intravitreal, subconjuntival, subretinal, sub-Tenon and 
suprachoroidal injections.  
 
Figure 6. Eye fundus photographs obtained at 40 days after the injection of 10 mg of 
unloaded (B) and dexamethasone-loaded PLGA microspheres (C) in an animal model 
of uveitis. An untreated group was used as control (A). From Barcia et al., 2009, with 
permission of Elsevier.   
 
  
Figure 7. In-vitro release rate of GDNF from PLGA microspheres (ng GDNF/mg 
microspheres) and SEM images of particles at different time points of the study. During 
the first 2 weeks of incubation, particles kept a smooth surface. After 4 weeks, the erosion 
of the surface of microparticles was evident, and 2 weeks later they started to aggregate. 
After 8 weeks of the release assay, microparticles were completely aggregated. 
  
Figure 8. GDNF/Vit E microspheres (0.64 ng GDNF/eye) increased retinal ganglion cells 
survival and axonal integrity in an animal model of glaucoma. A-E: effects of GDNF/VitE 
microspheres treatment on the survival of RGCs. (A) Normal retina without IOP 
elevation. GDNF/Vit E microspheres treatment (B) resulted in the preservation of RCGs 
compared with GDNF (C), Vitamin E (D) and blank microspheres (E). From Checa-
Casalengua et al., 2011, with permission of Elsevier.  F–O: effects of GDNF/Vit E 
microspheres treatment on axon survival due to chronic IOP elevation: normal ON axons 
without IOP elevation (F). GDNF/Vit E microspheres treatment (G) resulted in a 
preservation of axons compare with GDNF (H), Vit E (I) and blank microspheres (J). 
Corresponding representative EM photos (K–O). F–J: magnification 1000×; K–O: 
magnification 7100×. Quantitative analysis of GDNF/Vit E microspheres treatment on 
the survival of RGC (P). Chronic IOP elevation resulted in a significant loss of the RGC 
(p < 0.01). GDNF/Vit E microspheres treatment significantly increased the RGC survival 
compared GDNF, Vit E and blank microspheres treatment (p < 0.01). Quantitative 
analysis of GDNF microspheres treatment on the ON axon survival (Q). GDNF/Vit E 
microspheres treatment increased the survival percentage compared with GDNF, Vit E, 
and blank microspheres treatment (p < 0.01). From Checa-Casalengua et al., 2011. With 
permission of Elsevier.  
 
 
 
 
 
